Overview
TTRX market data
Price History
TTRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.57 – $26.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $245.8 · P/B 24.75.
Company News
8-K filing — Turn Therapeutics Inc. (TTRX)SEC EDGAR · Jul 28, 2026, 12:05 PM
Why Is Turn Therapeutics Stock Trading Higher Today?Benzinga · Jul 7, 2026, 6:25 PM
Turn Therapeutics Completes Comprehensive Interim Analysis Of Ongoing Adaptive Phase 2 Clinical Trial Evaluating GX-03 For Treatment Of Atopic DermatitisBenzinga · Jul 7, 2026, 12:15 PM
Turn Therapeutics To Present Data On Its Interim Analysis Of Its Current Adaptive Phase 2 Study Of GX-03 In Atopic DermatitisBenzinga · Jul 6, 2026, 8:05 PM
Turn Therapeutics shares are trading higher. The company announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with atopic dermatitis.Benzinga · Jun 1, 2026, 7:44 PM
Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic DermatitisBenzinga · Jun 1, 2026, 12:36 PM
Turn Therapeutics Publishes Peer-Reviewed Research Article Titled "Effects of extended-release topical polyhexanide in a Staphylococcus aureus-induced murine dermatitis model characterized by IL-36 expression" In Journal of Dermatological Treatment.Benzinga · May 27, 2026, 12:08 PM